What Does Conformis, Inc.'s (NASDAQ:CFMS) Balance Sheet Tell Us About It?

Conformis, Inc. (NASDAQ:CFMS) is a small-cap stock with a market capitalization of US$158m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. Why is it important? Since CFMS is loss-making right now, it’s essential to assess the current state of its operations and pathway to profitability. Let's work through some financial health checks you may wish to consider if you're interested in this stock. However, this is just a partial view of the stock, and I recommend you dig deeper yourself into CFMS here.

Advertisement

CFMS’s Debt (And Cash Flows)

Over the past year, CFMS has reduced its debt from US$30m to US$15m , which includes long-term debt. With this reduction in debt, CFMS's cash and short-term investments stands at US$24m , ready to be used for running the business. We note it produced negative cash flow over the last twelve months. As the purpose of this article is a high-level overview, I won’t be looking at this today, but you can assess some of CFMS’s operating efficiency ratios such as ROA here.

Can CFMS meet its short-term obligations with the cash in hand?

At the current liabilities level of US$11m, the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 4.22x. The current ratio is calculated by dividing current assets by current liabilities. Having said that, a ratio above 3x may be considered excessive by some investors.

NasdaqGS:CFMS Historical Debt, April 8th 2019
NasdaqGS:CFMS Historical Debt, April 8th 2019

Is CFMS’s debt level acceptable?

With a debt-to-equity ratio of 41%, CFMS can be considered as an above-average leveraged company. This is somewhat unusual for small-caps companies, since lenders are often hesitant to provide attractive interest rates to less-established businesses. Though, since CFMS is currently unprofitable, sustainability of its current state of operations becomes a concern. Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.

Next Steps:

CFMS’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow. This may mean this is an optimal capital structure for the business, given that it is also meeting its short-term commitment. I admit this is a fairly basic analysis for CFMS's financial health. Other important fundamentals need to be considered alongside. I recommend you continue to research Conformis to get a more holistic view of the small-cap by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for CFMS’s future growth? Take a look at our free research report of analyst consensus for CFMS’s outlook.
  2. Historical Performance: What has CFMS's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqCM:CFMS

Conformis

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.

Fair value with mediocre balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2540.0% undervalued
88 users have followed this narrative
0 users have commented on this narrative
22 users have liked this narrative
HE
HedgeY
IONQ logo
HedgeY on IonQ ·

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection

Fair Value:US$482.3% overvalued
33 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5450.7% undervalued
56 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
IV
NFLX logo
Ivoed on Netflix ·

Netflix’s Business Quality Is Clear. The Harder Question Is Whether The Stock Is Still Cheap

Fair Value:US$825.3% undervalued
29 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

MO
7974 logo
Momentum_Heron_abxu on Nintendo ·

Nintendo facing the Ram shortage situation

Fair Value:JP¥8k10.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LE
AEM logo
lenny67 on Agnico Eagle Mines ·

Is This Micro-Cap the Secret Solution to Agnico Eagle’s Multi-Year Production Crisis? (CSE: RFR | NYSE: AEM)

Fair Value:US$123.91k99.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LE
RFR logo
lenny67 on Renforth Resources ·

The Strategic Arbitrage at Parbec: Why Renforth Holds the Cards

Fair Value:CA$0.1586.7% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75028.1% undervalued
83 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9631.3% undervalued
63 users have followed this narrative
9 users have commented on this narrative
19 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0544.6% undervalued
56 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative